|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Im_Clone_Systems
|
|
gptkbp:activities
|
inhibits EGFR signaling
|
|
gptkbp:approves
|
gptkb:2004
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
chemotherapy
|
|
gptkbp:clinical_trial
|
gptkb:CRYSTAL_trial
gptkb:EXTREME_trial
combination therapy
Phase III
monotherapy
BMS-099 trial
NC T00002899
NC T00045032
NC T00045045
NC T00045046
NC T00045047
NC T00045048
NC T00045049
|
|
gptkbp:contraindication
|
pregnancy
lactation
history of severe infusion reactions
hypersensitivity to cetuximab
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Erbitux
|
|
gptkbp:indication
|
EGFR-expressing tumors
|
|
gptkbp:ingredients
|
C6420 H9920 N1716 O1980 S44
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:is_used_for
|
treatment of colorectal cancer
treatment of head and neck cancer
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:manufacturer
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
gptkb:Cetuximab
|
|
gptkbp:research_areas
|
oncology
biologics
targeted therapy
|
|
gptkbp:shelf_life
|
3 years
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
fever
vomiting
diarrhea
chills
skin rash
anaphylaxis
infusion reactions
dyspnea
hypomagnesemia
|
|
gptkbp:storage
|
2 to 8 ° C
|
|
gptkbp:targets
|
gptkb:EGFR
|
|
gptkbp:weight
|
145 k Da
|